Bio

Clinical Focus


  • Cancer > Gynecologic Cancer
  • Gynecologic Oncology
  • Surgical Procedures, Minimally Invasive

Academic Appointments


Professional Education


  • Fellowship:Alpert Medical School at Brown University (2011) RI
  • Residency:Greenville Hospital System University Medical Center (2006) SC
  • Medical Education:University of Florida (2002) FL

Research & Scholarship

Clinical Trials


  • Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Not Recruiting

    Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase II trial studies how well veliparib works in treating patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

    Stanford is currently not accepting patients for this trial. For more information, please contact Maureen Sutton, (650) 725 - 9167.

    View full details

  • Study of FP-1039 in Subjects With Endometrial Cancers Not Recruiting

    An open-label, non-randomized, single arm study to assess the safety, tolerability, and pharmacokinetics of FP-1039 given by weekly intravenous (IV) administrations in advanced endometrial cancer patients with FGFR2-specific mutations. FP-1039 will be dosed weekly starting at a dose of up to 16 mg/kg.

    Stanford is currently not accepting patients for this trial. For more information, please contact Dana Supan, (650) 736 - 1694.

    View full details

  • A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers Recruiting

    This is a study of CDX-1127, a therapy that targets the immune system and may act to promote anti-cancer effects. The study enrolls patients with hematologic cancers (certain leukemias and lymphomas), as well as patients with select types of solid tumors.

    View full details

  • A Study of GDC-0980 in the Treatment of Recurrent or Persistent Endometrial Carcinoma Not Recruiting

    This is a multicenter, single-arm, open-label Phase II study to evaluate the activity of GDC-0980 in patients with recurrent or persistent endometrial cancer. The safety, tolerability, and pharmacokinetics of GDC-0980 will also be evaluated.

    Stanford is currently not accepting patients for this trial. For more information, please contact Anthea Buchin, (650) 724 - 3155.

    View full details

Stanford Medicine Resources: